F-star Therapeutics (F-star Therapeutics) Days Sales Outstanding : 0.00 (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is F-star Therapeutics Days Sales Outstanding?

F-star Therapeutics's average Accounts Receivable for the three months ended in Sep. 2022 was $0.00 Mil. F-star Therapeutics's Revenue for the three months ended in Sep. 2022 was $1.13 Mil. Hence, F-star Therapeutics's Days Sales Outstanding for the three months ended in Sep. 2022 was 0.00.

The historical rank and industry rank for F-star Therapeutics's Days Sales Outstanding or its related term are showing as below:

FSTX's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.665
* Ranked among companies with meaningful Days Sales Outstanding only.

F-star Therapeutics's Days Sales Outstanding stayed the same from Sep. 2021 (0.00) to Sep. 2022 (0.00).

F-star Therapeutics Days Sales Outstanding Historical Data

The historical data trend for F-star Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

F-star Therapeutics Days Sales Outstanding Chart

F-star Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Days Sales Outstanding

F-star Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Days Sales Outstanding	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of F-star Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, F-star Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

F-star Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, F-star Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where F-star Therapeutics's Days Sales Outstanding falls into.

F-star Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

F-star Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2021 is calculated as

	Days Sales Outstanding (A: Dec. 2021 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2020 )	+	Accounts Receivable (A: Dec. 2021 ))	/	count )	/	Revenue (A: Dec. 2021 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	21.167	*	365
=	0					/	21.167	*	365
=	0.00

F-star Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2022 is calculated as:

	Days Sales Outstanding (Q: Sep. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2022 )	+	Accounts Receivable (A: Sep. 2022 ))	/	count )	/	Revenue (A: Sep. 2022 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	1.125	*	365 / 4
=	0					/	1.125	*	365 / 4
=	0.00

F-star Therapeutics (NAS:FSTX) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

F-star Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of F-star Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

F-star Therapeutics (F-star Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » F-star Therapeutics Inc (NAS:FSTX) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

Babraham Research Campus, Eddeva B920, Cambridge, GBR, CB22 3AT

Website

https://www.f-star.com

F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.

Executives

Geoffrey Race	director	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Edward Jr Benz	director	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Darlene M Deptula-hicks	officer: See Remarks	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Eliot Forster	director, officer: PRESIDENT AND CEO	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Nessan Bermingham	director	890 WINTER STREET, WALTHAM MA 02451
Louis Kayitalire	officer: CHIEF MEDICAL OFFICER	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Neil Brewis	officer: CHIEF SCIENTIFIC OFFICER	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pamela M. Klein	director	35 PARKWOOD DRIVE, SUITE 210, HOPKINTON MA 01748
Krol Patrick Johan Hendrik	director	GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Garrett Winslow	officer: General Counsel and Secretary	35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Lori Firmani	officer: VP of Finance and Treasurer	35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTCALS, INC., HOPKINTON MA 01748
Scott Andrew Smith	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Timothy P Clackson	director	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christiana Bardon	director, 10 percent owner	86 SOUTH STREET, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Mpm Oncology Impact Management Lp	10 percent owner	399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116